 Context Therapeutics Inc said it closed 2021 with a balance sheet of nearly 50 million. As of December 31, 2021, the womens oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers said its cash, cash equivalents, and restricted cash were 49.7 million -- compared to 0.3 million at the end of 2020. 